ECSP24007193A - Compuestos pirimidínicos para usar como inhibidores de map4k1 - Google Patents

Compuestos pirimidínicos para usar como inhibidores de map4k1

Info

Publication number
ECSP24007193A
ECSP24007193A ECSENADI20247193A ECDI202407193A ECSP24007193A EC SP24007193 A ECSP24007193 A EC SP24007193A EC SENADI20247193 A ECSENADI20247193 A EC SENADI20247193A EC DI202407193 A ECDI202407193 A EC DI202407193A EC SP24007193 A ECSP24007193 A EC SP24007193A
Authority
EC
Ecuador
Prior art keywords
map4k1
compounds
pyrimidine compounds
inhibitors
map4k1 inhibitors
Prior art date
Application number
ECSENADI20247193A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP24007193A publication Critical patent/ECSP24007193A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se dirige a compuestos de fórmula (I) y sales farmacéuticamente aceptables de este, que son útiles como inhibidores de MAP4K1, procesos para su preparación, composiciones farmacéuticas que comprenden los compuestos y el uso de los compuestos o las composiciones en el tratamiento o la prevención de varias enfermedades, afecciones y/o trastornos mediados por MAP4K1.
ECSENADI20247193A 2021-07-06 2024-01-26 Compuestos pirimidínicos para usar como inhibidores de map4k1 ECSP24007193A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202121030204 2021-07-06

Publications (1)

Publication Number Publication Date
ECSP24007193A true ECSP24007193A (es) 2024-03-01

Family

ID=82703212

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20247193A ECSP24007193A (es) 2021-07-06 2024-01-26 Compuestos pirimidínicos para usar como inhibidores de map4k1

Country Status (14)

Country Link
US (1) US12577267B2 (es)
EP (1) EP4367123A1 (es)
JP (1) JP2024527565A (es)
KR (1) KR20240012538A (es)
CN (1) CN117730083A (es)
AU (1) AU2022305807B2 (es)
CA (1) CA3223874A1 (es)
CL (1) CL2023003791A1 (es)
CO (1) CO2024000572A2 (es)
EC (1) ECSP24007193A (es)
IL (1) IL309342A (es)
MX (1) MX2023015246A (es)
PE (1) PE20240585A1 (es)
WO (1) WO2023281417A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024231875A1 (en) 2023-05-09 2024-11-14 Glenmark Specialty S.A. Hpk1 inhibitor for use in the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273224B2 (en) * 2013-08-22 2019-04-30 Jubilant Biosys Limited Substituted pyrimidine compounds, compositions and medicinal applications thereof
US11180482B2 (en) * 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
WO2021125803A1 (ko) * 2019-12-16 2021-06-24 한국화학연구원 신규한 피리미딘 유도체 및 이의 용도

Also Published As

Publication number Publication date
MX2023015246A (es) 2024-01-19
CL2023003791A1 (es) 2024-07-12
AU2022305807A1 (en) 2024-01-04
AU2022305807B2 (en) 2024-09-05
EP4367123A1 (en) 2024-05-15
IL309342A (en) 2024-02-01
PE20240585A1 (es) 2024-03-21
CA3223874A1 (en) 2023-01-12
WO2023281417A1 (en) 2023-01-12
US12577267B2 (en) 2026-03-17
KR20240012538A (ko) 2024-01-29
CO2024000572A2 (es) 2024-02-05
JP2024527565A (ja) 2024-07-25
CN117730083A (zh) 2024-03-19
US20230227483A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CO2021000537A2 (es) Inhibidores de inflamasoma nlrp3
CO2022015054A2 (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2
ECSP20040257A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CR11491A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
UY32848A (es) Compuestos heterocíclicos de oxima
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
MX2025010799A (es) Inhibidores de acilsulfonamida para lisina acetiltransferasa 6a (kat6a)
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
UY40587A (es) Inhibidores del inflamasoma nlrp3
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
CL2023003921A1 (es) Inhibidores de transglutaminasas
CO2024000572A2 (es) Compuestos pirimidínicos para usar como inhibidores de map4k1
CR20210661A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
UY30862A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacioon y aplicaciones
MX2021009584A (es) Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).